Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma- based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol 2019;5(2):173 – 80

Asao T, Takahashi F, Takahashi K. Resistance to molecularly targeted therapy in non-small-cell lung cancer. Respir Investig 2019;57(1):20 – 6

Auliac JB, Bayle S, Do P, et al. Efficacy of dabrafenib plus trametinib combi - nation in patients with BRAF V600E-mutant NSCLC in real-world setting: GFPC 01-2019. Cancers (Basel) 2020;12(12):3608

Bauer J, Wiesner T. Molekulare Diagnostik und Techniken. 2021. https://www. diagnostik-und-techniken?epediaDoi=10.1007%2F978-3-662-44367-5_4, abgerufen am: 03.06.2021

Bauml JM. Underdiagnosis of EGFR exon 20 insertion mutation variants: estimates from NGS-based real-world datasets WCLC 2020, Singapur, 28-31 Januar 2021

Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30(8):863 – 70

Burns TF, Borghaei H, Ramalingam SS, et al. Targeting KRAS-mutant non- small-cell lung cancer: one mutation at a time, with a focus on KRAS G12C mutations. J Clin Oncol 2020;38(35):4208 – 18

Chen D, Zhang LQ, Huang JF, et al. BRAF mutations in patients with non- small cell lung cancer: a systematic review and meta-analysis. PLoS One 2014;9(6):e101354

Cheng L, Alexander RE, Maclennan GT, et al. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol 2012;25(3):347 – 69

Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion- positive non-small-cell lung cancer. N Engl J Med 2020;383(9):813 – 24

Elliott J, Bai Z, Hsieh SC, et al. ALK inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis. PLoS One 2020;15(2):e0229179

Farago AF, Azzoli CG. Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer. Transl Lung Cancer Res 2017;6(5):550 – 9

Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 2015;5(8):850 – 9

Griesinger F, Felip E, Smit EF, et al. Tepotinib in patients with MET exon 14 skipping NSCLC: efficacy and safety by line of therapy (Poster 24P). European Lung Cancer Virtual Congress, 30.03.-02.04.2022, 2022

Gondos A, Paz-Ares LG, Saldana D, et al. Genomic testing among patients (pts) with newly diagnosed advanced non-small cell lung cancer (aNSCLC) in the United States: a contemporary clinical practice patterns study. J Clin Oncol 2020;38(15_suppl):9592

Hsu WH, Yang JC, Mok TS, et al. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol 2018;29(suppl_1):i3 – i9

Jordan EJ, Kim HR, Arcila ME, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov 2017;7(6):596 – 609

Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorse- ment of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology clinical practice guideline update. J Clin Oncol 2018;36(9):911 – 9

Kraywinkel K, Schönfeld I. Epidemiologie des nichtkleinzelligen Lungen- karzinoms in Deutschland. Der Onkologe 2018;24(12):946 – 51

Leitlinienprogramm Onkologie. S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms, Langversion 1.0, AWMF-Regis- ternummer: 020/007OL. 2018. Lungenkarzinom.98.0.html, abgerufen am: 17.12.2021

Liang H, Wang M. MET oncogene in non-small cell lung cancer: mechanism of MET dysregulation and agents targeting the HGF/c-Met axis. Onco Targets Ther 2020;13:2491 – 510

Lin JJ, Ritterhouse LL, Ali SM, et al. ROS1 fusions rarely overlap with other oncogenic drivers in non-small cell lung cancer. J Thorac Oncol 2017;12(5):872 – 7

Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011;29(26):3574 – 9

Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 2019;30(8):1321 – 8

Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a rando- mized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol 2018;36(22):2244-50

Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017;376(7):629 – 40

Muzzey D, Evans EA, Lieber C. Understanding the basics of NGS: from mechanism to variant calling. Curr Genet Med Rep 2015;3(4):158 – 65

Nowossadeck E, Haberland J, Kraywinkel K. Die künftige Entwicklung der Er- krankungszahlen von Darmkrebs und Lungenkrebs. Bundesgesundheits- blatt - Gesundheitsforschung - Gesundheitsschutz 2014;57(1):103 – 10

Onkopedia. Nicht-kleinzelliges Lungenkarzinom. 2021. https://www. kleinzellig-nsclc/@@guideline/html/index.html, abgerufen am: 03.09.2021

Ostermann H, Ukena D. Aktuelle Ergebnisse und Entwicklung des Testver- haltens beim NSCLC seit 2012. Journal Onkologie 07/08 2020

Papadimitrakopoulou VA, Wu YL, Han JY, et al. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. Ann Oncol 2018;29:viii741

Pennell NA, Zhou J, Hobbs B. A model comparing the value of broad next- gen sequencing (NGS)-based testing to single gene testing (SGT) in patients with nonsquamous non-small cell lung cancer (NSCLC) in the United States. J Clin Oncol 2020;38(15_suppl):9529

Planchard D, Besse B, Groen H, et al. Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2020a;38(15_suppl):9593

Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow- up. 2020b. clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer, abgerufen am: 05.05.2021

Ramalingam SS, Cheng Y, Zhou C, et al. Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol 2018;29:viii740

Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2019;382(1):41 – 50

Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemother- apy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13(3):239 – 46

Rossi G, Jocollé G, Conti A, et al. Detection of ROS1 rearrangement in non- small cell lung cancer: current and future perspectives. Lung Cancer (Auckl) 2017;8:45 – 55

Rote. Liste 2022., abgerufen am: 18.05.2022

Sacher AG, Dahlberg SE, Heng J, et al. Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer. JAMA Oncol 2016;2(3):313 – 20

Salgia R, Sattler M, Scheele J, et al. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treat Rev 2020;87:102022

Schrock AB, Frampton GM, Suh J, et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. J Thorac Oncol 2016;11(9):1493 – 502

Schuette W, Schirmacher P, Eberhardt WE, et al. EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study. Cancer Epidemiol Biomarkers Prev 2015;24(8):1254 – 61

Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol 2019;30(7):1121 – 6

Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011;17(8):2081 – 6

Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med 2021;384(25):2371 – 81

Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemother- apy in ALK-positive lung cancer. N Engl J Med 2014;371(23):2167 – 77

Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med 2017;378(2):113 – 25

Stenzinger A, van Tilburg CM, Tabatabai G, et al. Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen. Der Pathologe 2021;42(1):103 – 15

Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010;17(3):889 – 97

Thai AA, Solomon BJ, Sequist LV, et al. Lung cancer. Lancet 2021; 398(10299):535 – 54

Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 2013;19(11):1469 – 72

Vuong HG, Ho ATN, Altibi AMA, et al. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - a systematic review and meta-analysis. Lung Cancer 2018;123:76 – 82

Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012;30(35):4352 – 9

WHO. Cancer today - fact sheets lung. 2020. factsheets/cancers/15-Lung-fact-sheet.pdf, abgerufen am: 21.01.2021

Wolf J, Garon EB, Groen HJM, et al. Capmatinib in MET exon 14-mutated, advanced NSCLC: updated results from the GEOMETRY mono-1 study. J Clin Oncol 2021;39(15_suppl):9020

Wolf J, Seto T, Han J-Y, et al. Capmatinib in MET exon 14–mutated or MET- amplified non–small-cell lung cancer. N Engl J Med 2020;383(10):944 – 57

Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 2017;18(11):1454 – 66

Zentrum für Krebsregisterdaten. 2017. Krebs/DE/Content/Krebsarten/Lungenkrebs/lungenkrebs_node.html, abgerufen am: 12.01.2021

Zhang K, Chen H, Wang Y, et al. Clinical characteristics and molecular patterns of RET-rearranged lung cancer in chinese patients. Oncol Res 2019a;27(5):575 – 82

Zhang T, Wan B, Zhao Y, et al. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res 2019b;8(3):302 – 16

Zhang Z, Yang S, Wang Q. Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer. Biomarker Research 2019c;7(1):27

Zhao J, Xia Y. Targeting HER2 alterations in non-small-cell lung cancer: a comprehensive review. JCO Precision Oncology 2020; 10.1200/ PO.19.00333(4):411 – 25